Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Investor Presentation (February 2026)
34 slides from Botanix Pharmaceuticals's investor presentation, Feb 17, 2026
Slide 1: Botanix Pharmaceuticals Capital Raising Presentation
For personal use only Botanix Pharmaceuticals Capital Raising Presentation 17 February 2026 Not for release to US wire services or distribution in the United States www.botanixpharma.com
Slide 2: Important Notices & Disclaimer
Important Notices & Disclaimer The following notice and disclaimer applies to this investor presentation (“Presentation”) and you are therefore advised to read this This Presentation has been prepared by the Company with due care, but no representation or warranty, express or implied, is provided in
Slide 3: Important Notices & Disclaimer (cont.)
Important Notices & Disclaimer (cont.) 5. Investment risks There are a number of risks specific to the Raising, the Company and of a general nature which may affect the future operating and Except as required by law or regulation, Botanix undertakes no obligation to finalise, check, supplement, revi
Slide 4: Executive summary
Executive summary Strong growth of Sofdra® in the first 11 months of launch For personal use only 1 v 62,500 prescriptions shipped, $93.5m Gross Revenue, $21.2m Net Revenue v Product, sales force execution, and Botanix Fulfilment Platform exceeding expectations High performance Botanix Fulfilment Pl
Slide 5: Performance Update
For personal use only Performance Update www.botanixpharma.com 5
Slide 6: Three key pillars drive Botanix's near- and long-term value
Three key pillars drive Botanix’s near- and long-term value For personal use only Strong Opportunity Differentiated Solid Foundation for for Sofdra® Fulfilment Platform Growth & Profitability • Large underserved market of • Improves gross to net yield • Manufacturing efficiencies 10 million patients
Slide 7: Key accomplishments in last months from Sofdra launch to date
Key accomplishments in last 11 months from Sofdra® launch to date Cumulative Gross Revenue Cumulative Net Revenue Cumulative Total Prescriptions 100 25 70 For personal use only 60 80 $93.5 20 $21.2 50 62.5k 60 million 15 shipped million 40 thousands millions millions 10 30 40 20 20 5 10 0 0 0 CY2025
Slide 8: Q2 FY2026: Strong Sofdra TRx growth and highlights
Q2 FY2026: Strong Sofdra® TRx growth and highlights For personal use only 25,351 • Total prescriptions shipped grew 24% vs Q1 FY2026, driven by our TRx fulfilment platform and productive sales team $9.1m • Net revenue increased 28% quarter over quarter Net Revenue 24% • Gross to net yield continues
Slide 9: Sofdra TRx shipments grew to 25,351 in Q2 FY26
Sofdra® TRx shipments grew to 25,351 in Q2 FY26 Growth in Volume of Total Prescriptions Shipped +24% For personal use only 25.3k +50% 20.4k +323% 13.6k 3.2k Q3 FY2025 Q4 FY2025 Q1 FY2026 Q2 FY2026 Note: Data sourced from SendRx and subject to reconciliation, which may retroactively adjust figures; d
Slide 10: Net revenue is accelerating while gross to net yield improves
Net revenue is accelerating in step with prescription growth, while gross to net yield continues to improve Sofdra® Net Revenue GTN Yield* For personal use only +28% 23% 24% $9.1M 21% $7.1m 15% $4.3m $0.7m Q3 FY2025 Q4 FY2025 Q1 FY2026 Q2 FY2026 Q3 FY2025 Q4 FY2025 Q1 FY2026 Q2 FY2026 *The Company a
Slide 11: 90% of surveyed HCPs expect to increase Sofdra prescribing
90% of surveyed healthcare professionals (HCPs) expect to increase Sofdra® prescribing in the next six months Is your prescribing of Sofdra likely to increase or For personal use only decrease in the next 6 months? Percentage of Response Primary Drivers of Sofdra Prescriptions 86% • 35% Access/SendR
Slide 12: Platform primed for additional products
Platform primed for additional products Current platform provides unique capabilities and positions Botanix for future growth For personal use only Platform provides seamless fulfilment, Platform provides further opportunity with proven administrative and patient for expansion through the addition o
Slide 13: Catalysts to drive Botanix performance
Catalysts to drive Botanix performance* For personal use only Long IP runway to 2040 elevates Secure API supply Expand Sofdra Add new products Botanix value and bridge to licensing to other to the fulfilment alternate supplier proposition for regions for Deliver platform to mergers & which decreases
Slide 14: Botanix Overview
For personal use only Botanix Overview www.botanixpharma.com 14
Slide 15: Corporate overview: Growing dermatology pharmaceutical company
Corporate overview: Growing dermatology pharmaceutical company with high physician satisfaction for Sofdra® For personal use only Dermatology Focused Innovative Platform Capital Position Positioned for Growth Cash of A$31.5 million, and additional A$14.9 Sofdra is the first and Fulfilment platform 5
Slide 16: Botanix is led by an experienced group of dermatology executives
Botanix is led by an experienced group of dermatology executives with multiple successful exits >30 For personal use only VINCE IPPOLITO HOWIE MCKIBBON CAREY HERBERT CHRIS LESOVITZ successful Executive Chairman Chief Legal & Compliance Officer Chief Financial Officer, U.S. dermatology Chief Executiv
Slide 17: Primary hyperhidrosis affects ~16M Americans
Primary hyperhidrosis affects ~16M Americans Third largest patient category in dermatology 16.1m For personal use only US Population ~336m PRIMARY HYPERHIDROSIS PATIENTS Primary Hyperhidrosis ~16.1m Patients1 Primary Axillary Hyperhidrosis Patients1 ~10m 7.5m PSORIASIS PATIENTS 2 Patients Seeking ~3
Slide 18: Hyperhidrosis
Hyperhidrosis A medical condition where excessive sweating For personal use only occurs beyond what is needed to maintain normal body temperature 1 in 2 Patients have never discussed their excessive sweating with a healthcare provider4 Reported experiencing Reported that Anxiety and depression const
Slide 19: Sofdra has been embraced as a first line prescription treatment option
Sofdra® has been embraced as a first line prescription treatment option for hyperhidrosis patients OLDER PRESCRIPTION For personal use only ANTIPERSPIRANTS NEW CHEMICAL ENTITIES PRODUCTS INVASIVE PROCEDURES SURGERY OTC ALUMINUM CHLORIDE BOTOX INJECTION CUTTING NERVES REFORMULATED ORAL DRUG INTO A SO
Slide 20: Sofdra is the first and only new chemical entity for primary axillary hyperhidrosis
Sofdra® is the first and only new chemical entity for primary axillary hyperhidrosis, providing a safe and effective treatment option Sofdra binds selectively to M3 FDA-Approved Indication2 receptors in the sweat gland, For personal use only The treatment of primary axillary hyperhidrosis in adults
Slide 21: The Botanix Fulfilment Platform improves GtN yield and offers frictionless access
The Botanix Fulfilment Platform improves GtN yield and offers frictionless access to Sofdra® for dermatologists and patients For personal use only ü Seamless fulfilment Increase in reimbursed PRESCRIBER PATIENT PHARMACY WHOLESALER ü prescriptions CO-PAY DISCOUNT ü High refill adherence rates Consign
Slide 22: Negotiations for API supply expected to derisk and offer savings
Negotiations for API supply expected to derisk and offer savings v Negotiations are advanced with current API supplier for a revised API supply contract that envisages spreading the For personal use only purchase of API over future years. 1 v Separately, a selection process is underway for alternate
Slide 23: Capital Raising
For personal use only Capital Raising www.botanixpharma.com 23
Slide 24: Capital raising summary
Capital raising summary Botanix has received firm commitments for a two tranche non-underwritten placement of new fully paid ordinary shares in the Company (“New Shares”) at A$0.06 each (“Offer Price”) to sophisticated and institutional investors raising approximately A$40.0 million (before costs) (
Slide 25: Capital raising summary (cont.)
Capital raising summary (cont.) The Company will offer eligible Australian and New Zealand shareholders on the Company’s register as at 7.00pm (Sydney time) on Monday, 16 February 2026 the ability to participate in an underwritten SPP to raise approximately A$5.0 million, with the ability to accept
Slide 26: Use of funds
Use of funds API supply arrangements Uses1 A$m • As demonstrated, the vast majority of the funds raised from For personal use only the Raising are intended to be put towards the upcoming payments under the current API supply contract with Kaken Pharmaceuticals. Active Pharmaceutical Ingredient (API)
Slide 27: Proforma capital structure and cash balance
Proforma capital structure and cash balance Pro forma cash balance A$m Pro forma capital structure # on issue Cash balance (as at 31 December 2025) ~$31.5 million Shares For personal use only Tranche 1 of Placement Up to ~$14.9 million Current 1,970,102,820 Tranche 2 of Placement1 Up to ~$25.1 milli
Slide 28: Indicative timetable
Indicative timetable Event Date and time (Sydney time) 1 Trading Halt Friday, 13 February 2026 For personal use only SPP Record Date 7.00 pm, Monday, 16 February 2026 ASX Announcement and shares resume trading on ASX Tuesday, 17 February 2026 Settlement of Placement – Tranche 1 Monday, 23 February 2
Slide 29: Key Risks
Key Risks 1. Risks of the Raising Debt Facilities The Company has an existing debt facility with Kreos Capital VII (UK) Limited (“Kreos”) and its related entities for a loan of up to the euro Shareholder approval equivalent of US$30 million (“Kreos Facility”). The Kreos Facility is secured against a
Slide 30: Key Risks (cont.)
Key Risks (cont.) Supply chain and dependence on third parties Insurance Botanix depends on third parties for the supply of critical materials for the development, manufacture, distribution and commercialisation As a pharmaceutical company, Botanix may be exposed to product liability claims, recalls
Slide 31: Key Risks (cont.)
Key Risks (cont.) 5. IP / Licensing IT systems, privacy and cyber security The Company is subject to a number of risks associated with IT systems, privacy and cyber security, including non-compliance with privacy Licensors and data security laws, regulations and guidance, cyber security breaches, da
Slide 32: International Offer Restrictions
International Offer Restrictions This Presentation does not constitute an offer of Shares or Options of the Company in any jurisdiction in which it would be unlawful. In particular, this Presentation may not be distributed to any person, and the New Shares and the Options may not be offered or sold,
Slide 33: International Offer Restrictions (cont.)
International Offer Restrictions (cont.) United Kingdom This Presentation has not been delivered for approval to the Financial Conduct Authority in the United Kingdom and no prospectus (within the meaning of Regulation 21 of The Public Offers and Admissions to Trading Regulations 2024 (“POATRs”)) ha
Slide 34: Botanix Pharmaceuticals Capital Raising Presentation
For personal use only Botanix Pharmaceuticals Capital Raising Presentation 17 February 2026 www.botanixpharma.com
Botanix Pharmaceuticals — Investor Presentation (February 2026) on 6ix